EUVIMEDEUVIMED entdecken
Crossref

Drug‐likeness evaluation and inhibitory mechanism of the emodin derivative on cardiac fibrosis based on metastasis‐associated protein 3

Heng Liu, Runze Li, Zhixia Wang, Weina Han, Xiuxiu Sun, Xinxin Dong, Han Lou, Run Xu, Ange Hu, Denis Baranenko, Xue Bai, Dan Xiao iD und 1 weitere

British Journal of Pharmacology · 2025

DOI: 10.1111/bph.70012 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Pharmacology, 2025. Verfasst von Heng Liu und 12 weiteren Autor:innen. Beteiligte Einrichtung: Pharmaceutical Experiment Teaching Center, College of Pharmacy, Harbin Medical University, Harbin, China. Hauptthemen laut MEDLINE: Emodin. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Purpose Emodin inhibits cardiac fibrosis through metastasis‐associated protein 3 (MTA3), but its limited bioavailability hinders clinical application. To enhance emodin's clinical potential, a new derivative, emodin succinyl ethyl ester, was synthesised by modifying the 3′‐OH position. This study assessed its drug‐likeness, anti‐fibrotic properties and molecular mechanisms involving MTA3. Experimental Approach Drug‐likeness properties of the emodin derivative were evaluated using computational‐aided drug design (CADD). Transverse aortic constriction (TAC)‐induced cardiac fibrosis and Angiotensin II (Ang II)‐stimulated cardiac fibroblasts were used in vivo and ex vivo, respectively, to determine the effects of the emodin derivative on cardiac fibrosis and fibroblast transdifferentiation. Bioinformatics analysis, CADD, chromatin immunoprecipitation (ChIP), luciferase reporter assays and functional experiments were employed to predict, identify and validate the relationship between MTA3 and its upstream transcription factors. Key Results The emodin derivative exhibited superior drug‐likeness and anti‐fibrotic effects compared to emodin by effectively inhibiting cardiac fibroblast transdifferentiation and restored MTA3 expression. E2F1 was identified and validated as a transcriptional regulator, promoting α‐SMA and COL1A2 expression, and directly reducing MTA3 expression in cardiac fibroblasts. The emodin derivative demonstrated stronger binding to the E2F1 transcription site than emodin, reducing E2F1 expression and enhancing anti‐fibrotic action. Conclusions and Implications The emodin derivative shows improved drug‐likeness and potent inhibition of cardiac fibrosis by targeting E2F1, disrupting its pro‐fibrotic function, restoring MTA3 expression and halting fibrosis progression. This advances emodin derivative's potential as a clinical therapy for cardiac fibrosis and provides insights into its anti‐fibrotic mechanisms.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

EmodinAnimalsFibrosisMaleRatsFibroblastsRats, Sprague-DawleyCell TransdifferentiationCells, CulturedMyocardiumHumans

Stichwörter der Autor:innen

CADDEmodin derivativeMTA3cardiac fibrosis

Substanzen

Emodin

Autor:innen und Institutionen

  • Pharmaceutical Experiment Teaching Center, College of Pharmacy, Harbin Medical University, Harbin, China.
  • National and Local Joint Engineering Laboratory for Synthesis Transformation and Separation of Extreme Environmental Nutrients, Harbin Institute of Technology, Harbin, Heilongjiang, China.
  • Zhengzhou Research Institute, Harbin Institute of Technology, Zhengzhou, Henan, China.
  • Department of Pharmacy, the fourth people's hospital of Datong, Shanxi, China.
  • School of Life Sciences, Faculty of Ecotechnologies, ITMO University, St. Petersburg, Russia.
  • Key Laboratory of Tropical Biological Resources of Ministry of Education, School of Pharmaceutical Sciences Hainan University, Haikou, China.

ORCID-Profile: Dan Xiao

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Liu, H., Li, R., Wang, Z., Han, W., Sun, X., Dong, X., Lou, H., Xu, R., Hu, A., Baranenko, D., Bai, X., Xiao, D., & Lu, W. (2025). Drug‐likeness evaluation and inhibitory mechanism of the emodin derivative on cardiac fibrosis based on metastasis‐associated protein 3. British Journal of Pharmacology. https://doi.org/10.1111/bph.70012

Vancouver

Liu H, Li R, Wang Z, Han W, Sun X, Dong X, et al. Drug‐likeness evaluation and inhibitory mechanism of the emodin derivative on cardiac fibrosis based on metastasis‐associated protein 3. British Journal of Pharmacology. 2025. doi:10.1111/bph.70012

BibTeX
@article{Liu2025,
  author = {Liu, Heng and Li, Runze and Wang, Zhixia and Han, Weina and Sun, Xiuxiu and Dong, Xinxin and Lou, Han and Xu, Run and Hu, Ange and Baranenko, Denis and Bai, Xue and Xiao, Dan and Lu, Weihong},
  title = {Drug‐likeness evaluation and inhibitory mechanism of the emodin derivative on cardiac fibrosis based on metastasis‐associated protein 3},
  journal = {British Journal of Pharmacology},
  year = {2025},
  doi = {10.1111/bph.70012}
}
Kostenlos starten →